Evidence map›Paper›PMID 32349358›Full record

ArticleNutrients2020

Yuna Ha, Won-Hwi Lee, JaeWoo Jeong, Mira Park, Ju-Young Ko, Oh Wook Kwon, Jongsung Lee, Youn-Jung Kim

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 32 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Therapeutic Potential ofMarine drugs · 2025
    Review
  5. Review
  6. Preventive nutrition and food science · 2025
    Article
  7. Review
  8. Article
  9. The Ocean's Pharmacy: Health Discoveries in Marine Algae.Molecules (Basel, Switzerland) · 2024
    Review
  10. Article
  11. Article
  12. Anti-Inflammatory and Antiatopic Effects ofMolecules (Basel, Switzerland) · 2023
    Article
  13. Article
  14. Article
  15. International journal of molecular sciences · 2022
    Article
  16. Review
  17. Article
  18. Potential of Tamanu (Evidence-based complementary and alternative medicine : eCAM · 2021
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yuna HaResearch Institute of Basic Sciences, Incheon National University, Incheon 22012, Korea.
Won-Hwi LeeResearch Institute of Basic Sciences, Incheon National University, Incheon 22012, Korea.
JaeWoo JeongResearch Institute of Basic Sciences, Incheon National University, Incheon 22012, Korea.
Mira ParkResearch Institute of Basic Sciences, Incheon National University, Incheon 22012, Korea.
Ju-Young KoResearch Institute of Basic Sciences, Incheon National University, Incheon 22012, Korea.
Oh Wook KwonResearch Institute of Basic Sciences, Incheon National University, Incheon 22012, Korea.
Jongsung LeeDepartment of Genetic Engineering, College of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon City, Gyunggi Do 164-19, Korea.
Youn-Jung KimResearch Institute of Basic Sciences, Incheon National University, Incheon 22012, Korea.
Incheon National University · KRSungkyunkwan University · KR

Funding

Incheon National University Incheon National University Research Grant in 2017National Research Foundation of Korea NRF-2017R1A6A1A06015181
6 · The paper itself

Abstract

Pyropia yezoensis, a red alga, is popular and harvested a lot in East Asia and is famous for its medicinal properties attributable to its bioactive compounds including amino acids (porphyra-334 and shinorine, etc.), polysaccharides, phytosterols, and pigments, but its anti-inflammatory effect and mechanism of anti-atopic dermatitis (AD) have not been elucidated. In this study, we investigate the anti-AD effect of P. yezoensis extract (PYE) on mRNA and protein levels of the pro-inflammatory chemokines, thymus, and activation-regulated chemokine (TARC/CCL17) and macrophage-derived chemokine (MDC/CCL22), in human HaCaT keratinocyte cells treated to interferon (IFN)-γ or tumor necrosis factor (TNF)-α (10 ng/mL each). The effect of the PYE on extracellular signal-regulated kinase (ERK) and other mitogen-activated protein kinases (MAPKs) was related to its suppression of TARC and MDC production by blocking NF-κB activation in HaCaT cells. Furthermore, astaxanthin and xanthophyll from P. yezoensis were identified as anti-AD candidate compounds. These results suggest that the PYE may improve AD and contained two carotenoids by regulating pro-inflammatory chemokines.

Indexed as

Anti-Inflammatory AgentsChemokine CCL17Chemokine CCL22Dermatitis, AtopicDown-RegulationExtracellular Signal-Regulated MAP KinasesHaCaT CellsHumansInflammation MediatorsInterferon-gammaNF-kappa Bp38 Mitogen-Activated Protein KinasesPhytotherapyPlant ExtractsPorphyraTumor Necrosis Factor-alphaAnti-Inflammatory AgentsastaxanthineChemokine CCL17Chemokine CCL22Extracellular Signal-Regulated MAP KinasesInflammation MediatorsInterferon-gammaNF-kappa Bp38 Mitogen-Activated Protein KinasesPlant ExtractsTumor Necrosis Factor-alphaXanthophyllsADastaxanthinMDCmitogen-activated protein kinasesNF-κBPyropia yezoensisTARCxanthophyll

Identifiers

PMID32349358
PMCPMC7285056
OpenAlexW3020507559

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.